1 eas CA-AKI is associated with an increased relative risk of
serious, adverse 90-day outcomes, the incidence of clinically
2 No vaccine-related
serious adverse effects were found in the dose-ranging study
3 group and 7 (2.4%) in the control group reported at least 1
serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]
4 or due to adverse events (OR 2.65, 95% CI: 1.04-6.80), any
serious adverse event (OR 2.30, 95% CI: 1.18-4.48), serious a
5 At least 1
serious adverse event developed in 12 patients (24%) in the r
6 Peri-prosthetic joint infections (PJI) are a
serious adverse event following joint replacement surgeries;
7 ed by five participants randomised to rosuvastatin, and one
serious adverse event in each group.
8 Pneumonia was the only
serious adverse event in more than 2% of patients (seven [3%]
9 One 3-year-old patient had a
serious adverse event of accidental ribavirin overdose requir
10 had provided all outcome data at week 16-17, or sooner if a
serious adverse event requiring knowledge of the study drug o
11 At least one treatment-related
serious adverse event was reported in 25 (10%) patients in th
12 replacement (TPVR) is associated with a risk of procedural
serious adverse events (SAE) and exposure to ionizing radiati
13 The total incidence of AE and
serious adverse events (SAE) was calculated.
14 he end-of-treatment outcomes, culture-conversion rates, and
serious adverse events (SAEs) during treatment.
15 Endpoints were solicited/unsolicited and
serious adverse events (SAEs), biochemical/hematological para
16 aimed to evaluate the existing evidence for serious and non-
serious adverse events after ivermectin exposure in pregnant
17 There were no drug-related
serious adverse events and no treatment-related deaths.
18 rm use is not associated with an increased risk of death or
serious adverse events compared with allopurinol.
19 s 14 patients (30%) in the placebo group (with 6 infectious
serious adverse events developing among 4 patients [9%]).
20 The outcomes of these
serious adverse events included 16 deaths, 4 of which were co
21 trated that the regimen was safe, with no treatment-related
serious adverse events observed.
22 Nonfatal
serious adverse events occurred in 12/72 (16.7%) in the oral
23 Treatment-related
serious adverse events occurred in 25 (24%) patients and trea
24 Treatment-related
serious adverse events occurred in seven (12%) patients in th
25 No intervention-related
serious adverse events occurred, and few adverse effects occu
26 12 patients (24%) in the rituximab group (with 9 infectious
serious adverse events occurring among 6 patients [12%]) vers
27 No vaccine-related
serious adverse events or severe dengue virus disease were re
28 0), any serious adverse event (OR 2.30, 95% CI: 1.18-4.48),
serious adverse events related to abnormal liver function tes
29 was 238.09 (95% CI 232.71-243.57) per 100 patient-years and
serious adverse events was 12.63 (95% CI 11.41-13.94) per 100
30 The incidence of
serious adverse events was low and was similar in the vaccine
31 ul between-group difference in the incidence or severity of
serious adverse events was reported during the follow-up peri
32 The number of
serious adverse events was similar in both groups and unrelat
33 No
serious adverse events were attributed to dihydroartemisinin-
34 (95% CI 11.41-13.94) per 100 patient-years; the most common
serious adverse events were infections at 4.13 (95% CI 3.45-4
35 Adverse events and
serious adverse events were minimal, but 2 deaths (7.4%) occu
36 Two
serious adverse events were reported - both resolved without
37 Eight
serious adverse events were reported with capsular release an
38 Cumulative rates of
serious adverse events were similar in TAK-003 (4.0%) and pla
39 ents with the primary safety outcome (a composite of death,
serious adverse events, or clinical grade 3 or 4 adverse even
40 36 individuals had 63
serious adverse events, which included 25 suicide attempts an
41 inferior to interventional management, with a lower risk of
serious adverse events.
42 There were no clinically relevant treatment-related
serious adverse events.
43 s was halted early after two of the four patients developed
serious adverse events.
44 glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other
serious adverse events.
45 s of non-cardiac drugs on cardiac contractility can lead to
serious adverse events.
46 All subjects completed the study without any
serious adverse events.
47 rmed COVID-19, and safety, as measured by the occurrence of
serious adverse events.
48 There were no significant between-group differences in
serious adverse events.
49 ry safety outcomes included cumulative incidence rates for (
serious) adverse events.
50 17
serious adverse reactions occurred in 11 patients, and there